Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 1/20 | 0.58 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769421 | 1.00 | GRM1 (0.58) | GRM1S1PR1S1PR5TDP1MAPK1 | |
| SCHEMBL6898191 | 0.77 | GRM1 (0.67) | GRM1 | |
| SCHEMBL6770374 | 0.77 | GRM1 (0.73) | GRM1NPSR1 | |
| SCHEMBL29360760 | 0.73 | GRM1 (1.00) | GRM1 | |
| SCHEMBL186260 | 0.73 | GRM1 (1.00) | GRM1 | |
| SCHEMBL6769289 | 0.73 | GRM1 (0.53) | GRM1EPHX2KMT2AMEN1 | |
| SCHEMBL6770332 | 0.73 | GRM1 (0.58) | GRM1MAPK1KMT2AMAPTMEN1 | |
| SCHEMBL6776461 | 0.69 | GRM1 (0.53) | GRM1KMT2AMEN1 | |
| SCHEMBL6776455 | 0.69 | GRM1 (0.53) | GRM1KMT2AMEN1 | |
| SCHEMBL6771512 | 0.68 | GRM1 (0.53) | GRM1KMT2AMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723718-B2 | GLUTAMATERGIC ANTAGONIST AND AGONISTS; ANTIISCHEMIC AND ANTISPASMODIC AGENTS; BRAIN AND NERVOUS SYSTEM DISORDERS; TRAUMA | BAYER AKTIENGESELLSCHAFT (DE) | 2004-04-20 | — | — | US | disclosed |
| US-20030158424-A1 | Substituted alpha, beta-anellated butyrolactones | STOLLE ANDREAS (DE) | 2003-08-21 | — | — | US | disclosed |
| US-6462074-B1 | Substituted α, β-anellated butyrolactones | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-08 | — | — | US | disclosed |
| EP-1047684-B1 | SUBSTITUTED ALPHA,BETA-ANELLATED BUTYROLACTONES | BAYER AG (DE) | 2002-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158424-A1 | Substituted alpha, beta-anellated butyrolactones | GABRB2, GABRB3, GABRB1 | GRM1 74/4885S1PR1 3800/4885S1PR5 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.